In 2026, Shanghai is a global hub for cellular immunotherapy. The best CAR-T therapy hospitals in Shanghai include Shanghai Ruijin Hospital, Shanghai GoBroad Cancer Hospital, and Jiahui International Hospital. These facilities provide international patients with cutting-edge treatments like Fucaso and Relma-cel, often at a CAR-T cell therapy cost in China that is 70% lower than US benchmarks.
Key Facts
- CAR-T therapy in Shanghai costs $60,000—$150,000 USD in 2026 — approximately 70% less than US benchmarks.
- Shanghai Ruijin Hospital reported a 94.4% overall response rate in its novel GPRC5D-targeted CAR-T trials (early 2026), making it arguably the most prestigious hematology center in Asia.
- Shanghai Jiahui International Hospital, a JCI-accredited partner of Massachusetts General Hospital, successfully achieved MRD negativity in a 78-year-old patient within 2 weeks of CAR-T infusion.
- International patients must submit recent PET-CT scans and pathology reports for eligibility review before receiving a medical invitation letter required for visa entry.
- Fudan University Shanghai Cancer Center (FUSCC) is conducting CD70-targeted CAR-T trials for liver cancer, making Shanghai one of the few cities offering solid-tumor CAR-T outside of lymphoma and leukemia.
Table of Contents
Why Choose Shanghai for CAR-T?
Shanghai combines China’s most advanced research institutions with world-class international patient infrastructure. The city offers CAR-T treatments at costs approximately 70% lower than US benchmarks, along with dedicated bilingual coordination at every major center. CAR-T cell therapy was first approved in the United States in 2017 and has since transformed the treatment of relapsed or refractory B-cell malignancies and multiple myeloma.
The Top 5 Hospital Profiles
1. Shanghai Ruijin Hospital (Jiao Tong University)
- Specialty: Complex blood cancers, relapsed Multiple Myeloma, novel GPRC5D-targeted CAR-T
- Notable: 94.4% overall response rate in GPRC5D-targeted CAR-T trials (early 2026); arguably the most prestigious hematology center in Asia. A landmark 2022 study published in the New England Journal of Medicine (PMID 35381195) demonstrated the strong efficacy of GPRC5D-targeted CAR-T in heavily pre-treated myeloma patients, forming the scientific foundation for Ruijin’s ongoing trials
- International services: International Medical Center with bilingual support
- Internal profile: Ruijin Hospital IMC
- External link: ASH 2024 publication — GPRC5D-targeted CAR-T trial data
- Estimated cost: $60,000—$90,000 USD
2. Shanghai GoBroad Cancer Hospital
- Specialty: Dual-target CAR-T (CD19+CD22); precision medicine for leukemia and lymphoma
- Location: Shanghai Pilot Free Trade Zone
- International services: S2 Medical Visa support, English-speaking care coordinators
- Website: GoBroad Healthcare Group
- Estimated cost: $80,000—$120,000 USD
3. Shanghai Jiahui International Hospital
- Specialty: Western-standard inpatient CAR-T with China’s cell manufacturing capacity
- Notable: JCI-accredited; formal partner of Massachusetts General Hospital; supports direct insurance billing; achieved MRD negativity in a 78-year-old patient within 2 weeks
- Internal profile: Jiahui International Hospital
- Website: jiahui.com
- Estimated cost: $100,000—$150,000 USD
4. Fudan University Shanghai Cancer Center (FUSCC)
- Specialty: CAR-T for solid tumors; CD70-targeted trials for liver cancer; GPC3-targeting for gastric and pancreatic cancer
- Notable: Pioneering CAR-T applications beyond lymphoma and leukemia into gastric, pancreatic, and liver cancers
- Internal profile: Fudan University Cancer Center
- Website: shca.org.cn
5. Zhongshan Hospital (Fudan University)
- Specialty: Hypoxia-inducible CAR-T cells for Stage IV gastric cancer; multidisciplinary approach
- Internal profile: Zhongshan Hospital Fudan University
- Website: zs-hospital.sh.cn
Comparing the Cost among the best CAR-T therapy hospitals in Shanghai
| Hospital | Estimated Total Cost (USD) |
|---|---|
| Shanghai Ruijin Hospital | $60,000—$90,000 |
| Shanghai GoBroad Cancer Hospital | $80,000—$120,000 |
| Shanghai Jiahui International Hospital | $100,000—$150,000 |
| Fudan University Shanghai Cancer Center | Available on assessment |
| Zhongshan Hospital (Fudan) | Available on assessment |
| General Shanghai range | $60,000—$150,000 |
Shanghai CAR-T pricing is approximately 70% lower than comparable treatment in the United States. The FDA approved tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) as the foundational commercial CAR-T products, with US list prices exceeding $400,000 — setting the benchmark against which China’s pricing advantage is measured.
How to Apply as an International Patient
International patients must submit recent PET-CT scans, pathology reports, and full medical history to the hospital’s international department for eligibility review. Upon approval, the hospital issues a medical invitation letter required for the S2 Medical Visa application.
For patients considering broader cancer treatment options beyond CAR-T, our Cancer Treatment in China guide covers immunotherapy, surgery, and proton therapy.
Frequently Asked Questions
How much does CAR-T therapy cost in Shanghai?
CAR-T therapy in Shanghai typically ranges from $60,000 to $150,000 USD depending on the hospital and complexity of treatment.
Can international patients receive CAR-T therapy in Shanghai?
Yes. Major Shanghai hospitals have international departments that assist with medical visas, medical invitation letters, and English-speaking coordination. MSK’s CAR-T program illustrates the global standard for CAR-T infrastructure that Shanghai’s leading hospitals now match in clinical capability, often at a fraction of the cost.
What documents are required to apply for CAR-T therapy in Shanghai?
Patients must submit recent PET-CT scans, pathology reports, and medical history to the hospital’s international department for eligibility review.
